Vialase Announces Positive Results of First In-Human Study of Femtosecond Laser Image-Guided High-Precision Trabeculotomy (FLigHT)

ViaLase, Inc., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm with the development of a truly non-invasive image-guided femtosecond laser treatment to enhance glaucoma patient care, today announced positive results of the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with the ViaLase technology.